Citable company snapshot
Edwards Lifesciences's latest SEC-sourced 2026-03-31 period shows $1.65B in revenue and $380.70M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:RevenueFromContractWithCustomerExcludingAssessedTax | Mar 31, 2026 | $1.65B | $1.57B | +5.0% |
| xbrl:GrossProfit | Mar 31, 2026 | $1.29B | $1.23B | +4.8% |
| xbrl:OperatingIncomeLoss | Mar 31, 2026 | $477.60M | $151.10M | +216.1% |
| xbrl:NetIncomeLoss | Mar 31, 2026 | $380.70M | $91.20M | +317.4% |
| xbrl:NetCashProvidedByUsedInOperatingActivities | Mar 31, 2026 | $43.80M | $450.90M | -90.3% |
| Free Cash Flow (computed) | Mar 31, 2026 | $-21.10M | $353.50M | -106.0% |
Source: SEC EDGAR XBRL; period Mar 31, 2026; filed May 6, 2026; accession 0001099800-26-000026.
Continue research
Follow same-sector companies and source explainers connected to the financials view.
A factual guide to free cash flow — how it is built from the cash flow statement, why presentations differ, and how Aerarium Research shows the source.
A factual guide to working capital, current assets, current liabilities, and the operating cash cycle.
A factual guide to stock-based compensation, how it appears in company filings, and why it connects cash flow to share count.
A factual guide to goodwill, intangible assets, acquisitions, and impairment charges in company financial statements.
